News
Infectex initiates enrollment in SQ109 Phase IIb-III trial for MDR-TB
www.news-medical.net
Infectex, a Russian biotech company in Maxwell Biotech Venture Fund's portfolio, announced today enrollment of the first patients in its Phase IIb-III clinical...
A cycle of actions dedicated to the 80th anniversary of the Shukhov...
en.krd.ru
The first event out of a cycle of thematic actions coincided with the 80th anniversary of Krasnodar Shukhov water tower took place in the city today.
Maxwell Biotech Venture Fund's Portfolio Company Infectex Enrolls ...infectex.ru/.../maxwell-biotech-venture-funds-portfolio-company-infectex-enrolls-firs...
infectex.ru
Oksana Markova, CEO of Infectex, said, “We are happy to announce the first Russian MDR-TB patients dosed with drug in this important clinical ...
sorted by relevance / date